open access

Vol 25, No 4 (2018)
Original articles — Clinical cardiology
Published online: 2017-09-13
Get Citation

Adiponectin correlates with body mass index and to a lesser extent with left ventricular mass in dialysis patients

Afrim Poniku, Gani Bajraktari, Shpend Elezi, Pranvera Ibrahimi, Michael Y. Henein
DOI: 10.5603/CJ.a2017.0108
·
Pubmed: 28980284
·
Cardiol J 2018;25(4):501-511.

open access

Vol 25, No 4 (2018)
Original articles — Clinical cardiology
Published online: 2017-09-13

Abstract

Background: Adiponectin is a serum protein produced by adipose tissue which exerts anti-inflammatory, anti-diabetic and anti-atherosclerotic properties, hence is considered a cardio-protective marker. With the current uncertain role of adiponectin in dialysis patients to the aim of this study was to investigate its relationship with left ventricular (LV) structure and function in these patients.
Methods: This study included 89 (age 56 ± 13 years, 43% male) patients treated with regular dialysis for > 6 months, and 55 control subjects with normal renal function. A complete two-dimensional, M-mode and tissue-Doppler echocardiographic study, and biochemical blood analyses, adiponectin and anthropometric parameters were obtainedon the same day.
Results: Dialysis patients had lower body mass index (BMI) and lower body surface area (BSA) (p < 0.001 for both), lower waist/hips ratio (p = 0.005), higher LV mass index (LVMI, p < 0.001), higher adiponectin level (p < 0.001) and LV end-systolic volume (p = 0.003), lower LV ejection fraction (p = 0.006), longer isovolumic relaxation time (p < 0.001), lower mean LV strain (p = 0.002), larger left atrium volume (p = 0.022) and lower left atrium emptying fraction (p = 0.026), compared to controls. In dialysis patients, adiponectin correlated with waist circumference (r = –0.427, p < 0.001), BMI (r = –0.403, p < 0.001) and BSA (r = –0.480, p < 0.001), and to a lesser extent with LVMI (r = 0.296, p = 0.005), waist/hips ratio (r = –0.222, p = 0.037) and total cholesterol (r = –0.292, p = 0.013). But in controls, it correlated only modestly with age (r = 0.304, p = 0.024), hemoglobin (r = 0.371, p = 0.005), high density lipoprotein cholesterol (r = 0.315, p = 0.019) and LVMI (r = 0.277, p = 0.043).
Conclusions: It seems that in dialysis patients, adiponectin modest correlation with anthropometric measurements suggests an ongoing catabolic process rather than a change in ventricular function.

Abstract

Background: Adiponectin is a serum protein produced by adipose tissue which exerts anti-inflammatory, anti-diabetic and anti-atherosclerotic properties, hence is considered a cardio-protective marker. With the current uncertain role of adiponectin in dialysis patients to the aim of this study was to investigate its relationship with left ventricular (LV) structure and function in these patients.
Methods: This study included 89 (age 56 ± 13 years, 43% male) patients treated with regular dialysis for > 6 months, and 55 control subjects with normal renal function. A complete two-dimensional, M-mode and tissue-Doppler echocardiographic study, and biochemical blood analyses, adiponectin and anthropometric parameters were obtainedon the same day.
Results: Dialysis patients had lower body mass index (BMI) and lower body surface area (BSA) (p < 0.001 for both), lower waist/hips ratio (p = 0.005), higher LV mass index (LVMI, p < 0.001), higher adiponectin level (p < 0.001) and LV end-systolic volume (p = 0.003), lower LV ejection fraction (p = 0.006), longer isovolumic relaxation time (p < 0.001), lower mean LV strain (p = 0.002), larger left atrium volume (p = 0.022) and lower left atrium emptying fraction (p = 0.026), compared to controls. In dialysis patients, adiponectin correlated with waist circumference (r = –0.427, p < 0.001), BMI (r = –0.403, p < 0.001) and BSA (r = –0.480, p < 0.001), and to a lesser extent with LVMI (r = 0.296, p = 0.005), waist/hips ratio (r = –0.222, p = 0.037) and total cholesterol (r = –0.292, p = 0.013). But in controls, it correlated only modestly with age (r = 0.304, p = 0.024), hemoglobin (r = 0.371, p = 0.005), high density lipoprotein cholesterol (r = 0.315, p = 0.019) and LVMI (r = 0.277, p = 0.043).
Conclusions: It seems that in dialysis patients, adiponectin modest correlation with anthropometric measurements suggests an ongoing catabolic process rather than a change in ventricular function.

Get Citation

Keywords

adiponectin; dialysis; left ventricular mass; body mass index

About this article
Title

Adiponectin correlates with body mass index and to a lesser extent with left ventricular mass in dialysis patients

Journal

Cardiology Journal

Issue

Vol 25, No 4 (2018)

Pages

501-511

Published online

2017-09-13

DOI

10.5603/CJ.a2017.0108

Pubmed

28980284

Bibliographic record

Cardiol J 2018;25(4):501-511.

Keywords

adiponectin
dialysis
left ventricular mass
body mass index

Authors

Afrim Poniku
Gani Bajraktari
Shpend Elezi
Pranvera Ibrahimi
Michael Y. Henein

References (42)
  1. Mitsuhashi H, Yatsuya H, Tamakoshi K, et al. Adiponectin level and left ventricular hypertrophy in Japanese men. Hypertens Dallas Tex 1979. 2007; 49(6): 1448–1454.
  2. Wiecek A, Adamczak M, Chudek J. Adiponectin--an adipokine with unique metabolic properties. Nephrol Dial Transplant. 2007; 22(4): 981–988.
  3. Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999; 100(25): 2473–2476.
  4. Komaba H, Igaki N, Goto S, et al. Adiponectin is associated with brain natriuretic peptide and left ventricular hypertrophy in hemodialysis patients with type 2 diabetes mellitus. Nephron Clin Pract. 2007; 107(3): c103–c108.
  5. Scherer PE, Williams S, Fogliano M, et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem. 1995; 270(45): 26746–26749.
  6. Goldstein BJ, Scalia R. Adiponectin: A novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab. 2004; 89(6): 2563–2568.
  7. Ebinç H, Ebinç FA, Ozkurt ZN, et al. Impact of adiponectin on left ventricular mass index in non-complicated obese subjects. Endocr J. 2008; 55(3): 523–528.
  8. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001; 86(5): 1930–1935.
  9. Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab. 2002; 87(6): 2764–2769.
  10. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000; 20(6): 1595–1599.
  11. Della Mea P, Lupia M, Bandolin V, et al. Adiponectin, insulin resistance, and left ventricular structure in dipper and nondipper essential hypertensive patients. Am J Hypertens. 2005; 18(1): 30–35.
  12. Foley RN. Clinical epidemiology of cardiac disease in dialysis patients: left ventricular hypertrophy, ischemic heart disease, and cardiac failure. Semin Dial. 2003; 16(2): 111–117.
  13. Pischon T, Girman CJ, Hotamisligil GS, et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004; 291(14): 1730–1737.
  14. Shibata R, Ouchi N, Ito M, et al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med. 2004; 10(12): 1384–1389.
  15. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990; 322(22): 1561–1566.
  16. Verdecchia P, Schillaci G, Borgioni C, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation. 1998; 97(1): 48–54.
  17. Stack AG, Saran R. Clinical correlates and mortality impact of left ventricular hypertrophy among new ESRD patients in the United States. Am J Kidney Dis. 2002; 40(6): 1202–1210.
  18. Silberberg JS, Barre PE, Prichard SS, et al. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int. 1989; 36(2): 286–290.
  19. Mallamaci F, Zoccali C, Cuzzola F, et al. Adiponectin in essential hypertension. J Nephrol. 2002; 15(5): 507–511.
  20. Kazumi T, Kawaguchi A, Sakai K, et al. Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure. Diabetes Care. 2002; 25(6): 971–976.
  21. Adamczak M, Wiecek A, Funahashi T, et al. Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens. 2003; 16(1): 72–75.
  22. Furuhashi M, Ura N, Higashiura K, et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertens Dallas Tex. 2003; 42(1): 76–81.
  23. Ayerden Eb, Ebinç H, Derici U, et al. The relationship between adiponectin levels and proinflammatory cytokines and left ventricular mass in dialysis patients. J Nephrol. 2009; 22(2): 216–223.
  24. Becker B, Kronenberg F, Kielstein JT, et al. MMKD Study Group. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol. 2005; 16(4): 1091–1098.
  25. Frystyk J, Tarnow L, Hansen TK, et al. Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia. 2005; 48(9): 1911–1918.
  26. Komaba H, Igaki N, Goto S, et al. Increased serum high-molecular-weight complex of adiponectin in type 2 diabetic patients with impaired renal function. Am J Nephrol. 2006; 26(5): 476–482.
  27. Zoccali C, Mallamaci F, Tripepi G, et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol. 2002; 13(1): 134–141.
  28. Tanita T, Miyakoshi H, Nakano Y. Performance of ELISA for specific measurement of high-molecular-weight (HMW) adiponectin. J Immunol Methods. 2008; 333(1-2): 139–146.
  29. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986; 57(6): 450–458.
  30. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation. 1977; 55(4): 613–618.
  31. de Simone G, Daniels SR, Devereux RB, et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol. 1992; 20(5): 1251–1260.
  32. Gosse P, Jullien V, Jarnier P, et al. Echocardiographic definition of left ventricular hypertrophy in the hypertensive: which method of indexation of left ventricular mass? J Hum Hypertens. 1999; 13(8): 505–509.
  33. Bajraktari G, Berbatovci-Ukimeraj M, Hajdari A, et al. Predictors of increased left ventricular filling pressure in dialysis patients with preserved left ventricular ejection fraction. Croat Med J. 2009; 50(6): 543–549.
  34. Özkan B, Açar G, Alıcı G, et al. Decreased plasma adiponectin is associated with impaired left ventricular longitudinal systolic function in hypertensive patients: a two-dimensional speckle tracking study. Clin Exp Hypertens. 2014; 36(1): 46–51.
  35. Duncan AM, Francis DP, Henein MY, et al. Importance of left ventricular activation in determining myocardial performance (Tei) index: comparison with total isovolumic time. Int J Cardiol. 2004; 95(2-3): 211–217.
  36. Tei C, Ling LH, Hodge DO, et al. New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function--a study in normals and dilated cardiomyopathy. J Cardiol. 1995; 26(6): 357–366.
  37. Galderisi M, Henein MY, D'hooge J, et al. Recommendations of the European Association of Echocardiography: how to use echo-Doppler in clinical trials: different modalities for different purposes. Eur J Echocardiogr. 2011; 12(5): 339–353.
  38. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005; 18(12): 1440–1463.
  39. Yoshida T, Delafontaine P. Mechanisms of cachexia in chronic disease states. Am J Med Sci. 2015; 350(4): 250–256.
  40. Paoletti E, De Nicola L, Gabbai FB, et al. Associations of left ventricular hypertrophy and geometry with adverse outcomes in patients with CKD and hypertension. Clin J Am Soc Nephrol. 2016; 11(2): 271–279.
  41. Koulouris SN, Kostopoulos KG, Triantafyllou KA, et al. Impaired systolic dysfunction of left ventricular longitudinal fibers: a sign of early hypertensive cardiomyopathy. Clin Cardiol. 2005; 28(6): 282–286.
  42. Amira OC, Naicker S, Manga P, et al. Adiponectin and atherosclerosis risk factors in African hemodialysis patients: a population at low risk for atherosclerotic cardiovascular disease. Hemodial Int Int Symp Home Hemodial. 2012; 16(1): 59–68.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl